Replimune Group Inc. (NASDAQ: REPL) Soars on Landmark FDA Approval for Skin Cancer Drug Tudriqev
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameReplimune Group, Inc.
-
Registration countryUSA
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









